Macular degeneration drug approval is a significant milestone for Olix, enhancing its global licensing strategy.
clinical trials
Avidity acquisition news: The Worst Phase 3 Setback Revealed
Avidity acquisition news reveals the latest Phase 3 setback for Novartis’ dystrophy drug, raising concerns in the pharma industry.